MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
electroCore EBITDA 2011-2026 | ECOR
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA electroCore
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.7 M | -11.4 M | -18.3 M | -22.3 M | -19.7 M | -24.3 M | -43.8 M | -54.5 M | -25.6 M | -15 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -11.4 M | -54.5 M | -24.8 M |
Quarterly EBITDA electroCore
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | -3.64 M | - | - | - | -6.08 M | - | -5.16 M | -5.82 M | -5.48 M | - | -3.7 M | -5.2 M | -5.29 M | - | -4.2 M | -5.73 M | -7.92 M | - | -10.7 M | -12.4 M | -14.2 M | -15.7 M | -13.5 M | -16.2 M | -9.09 M | -7.48 M | -5.98 M | -7.42 M | -4.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.64 M | -16.2 M | -7.98 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M |  USA |
 |
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | USA |
 |
iRhythm Technologies
IRTC
|
-36.7 M | $ 122.35 | 0.73 % | $ 3.92 B | USA |
 |
Alcon
ALC
|
580 M | $ 75.8 | -0.08 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
-2.16 M | $ 3.96 | -0.75 % | $ 183 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-11.8 M | $ 10.99 | 1.48 % | $ 26.7 M | USA |
 |
The Cooper Companies
COO
|
1.06 B | $ 64.42 | -0.82 % | $ 12.8 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | USA |
 |
Haemonetics Corporation
HAE
|
337 M | $ 59.93 | 0.52 % | $ 3.02 B | USA |
 |
ICU Medical
ICUI
|
244 M | $ 124.82 | 0.22 % | $ 3.08 B | USA |
 |
Envista Holdings Corporation
NVST
|
332 M | $ 26.8 | -0.89 % | $ 4.5 B | USA |
 |
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
3.55 B | $ 482.22 | 0.71 % | $ 172 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.5 M | $ 23.02 | -5.07 % | $ 1.55 B | USA |
 |
Glaukos Corporation
GKOS
|
-95 M | $ 121.48 | 0.5 % | $ 5.88 B | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 2.2 | 0.92 % | $ 101 M |  Israel |
 |
STAAR Surgical Company
STAA
|
-83.4 M | $ 25.67 | 3.34 % | $ 1.27 B | USA |
 |
STERIS plc
STE
|
1.34 B | $ 221.8 | -0.77 % | $ 21.9 B | USA |
 |
Masimo Corporation
MASI
|
-164 M | $ 178.63 | -0.04 % | $ 9.52 B | USA |
 |
Milestone Scientific
MLSS
|
-5.62 M | $ 0.32 | -1.27 % | $ 26.3 M | USA |
 |
InfuSystem Holdings
INFU
|
15 M | $ 10.34 | 0.68 % | $ 214 M | USA |
 |
Stereotaxis
STXS
|
-21.5 M | $ 1.93 | -1.53 % | $ 176 M | USA |
 |
Merit Medical Systems
MMSI
|
308 M | $ 68.58 | -0.04 % | $ 4.06 B | USA |
 |
Teleflex Incorporated
TFX
|
192 M | $ 136.56 | -0.07 % | $ 6.09 B | USA |
 |
Utah Medical Products
UTMD
|
12.2 M | $ 67.17 | -1.03 % | $ 218 M | USA |
 |
West Pharmaceutical Services
WST
|
756 M | $ 306.16 | -1.14 % | $ 22.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-70 M | $ 11.91 | 0.08 % | $ 2.37 B | USA |
 |
Retractable Technologies
RVP
|
-13.4 M | $ 0.65 | 0.2 % | $ 19.5 M | USA |
 |
Pro-Dex
PDEX
|
11.9 M | $ 52.1 | 2.24 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
78.3 M | $ 113.45 | 0.49 % | $ 2.57 B | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
-1.97 M | $ 21.38 | -1.57 % | $ 985 M | USA |
 |
Baxter International
BAX
|
673 M | $ 18.16 | -1.39 % | $ 9.32 B | USA |
 |
ResMed
RMD
|
1.16 B | $ 219.85 | 0.15 % | $ 32.1 B | USA |
 |
AtriCure
ATRC
|
2.64 M | $ 29.28 | 3.79 % | $ 1.4 B | USA |
 |
Harvard Bioscience
HBIO
|
-46.8 M | $ 6.86 | 1.18 % | $ 305 M | USA |
 |
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
-14.2 M | $ 11.1 | -0.89 % | $ 453 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.04 B | $ 152.14 | -1.74 % | $ 43.8 B | USA |
 |
Nephros
NEPH
|
-1.38 M | $ 2.87 | 1.06 % | $ 29.8 M | USA |
 |
OraSure Technologies
OSUR
|
-61.8 M | $ 3.0 | -1.64 % | $ 220 M | USA |
 |
Repligen Corporation
RGEN
|
116 M | $ 117.6 | 3.1 % | $ 6.55 M | USA |